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Abstract
Absence of part or all of the iris, aniridia, is a feature of several genetically distinct conditions. This review focuses on iris 
development and then the clinical features and molecular genetics of these iris malformations. Classical aniridia, a panocular 
eye malformation including foveal hypoplasia, is the archetypal phenotype associated with heterozygous PAX6 loss-of-
function mutations. Since this was identified in 1991, many genetic mechanisms of PAX6 inactivation have been elucidated, 
the commonest alleles being intragenic mutations causing premature stop codons, followed by those causing C-terminal 
extensions. Rarely, aniridia cases are associated with FOXC1, PITX2 and/or their regulatory regions. Aniridia can also occur 
as a component of many severe global eye malformations. Gillespie syndrome—a triad of partial aniridia, non-progressive 
cerebellar ataxia and intellectual disability—is phenotypically and genotypically distinct from classical aniridia. The causa-
tive gene has recently been identified as ITPR1. The same characteristic Gillespie syndrome-like iris, with aplasia of the 
pupillary sphincter and a scalloped margin, is seen in ACTA2-related multisystemic smooth muscle dysfunction syndrome. 
WAGR syndrome (Wilms tumour, aniridia, genitourinary anomalies and mental retardation/intellectual disability), is caused 
by contiguous deletion of PAX6 and WT1 on chromosome 11p. Deletions encompassing BDNF have been causally implicated 
in the obesity and intellectual disability associated with the condition. Lastly, we outline a genetic investigation strategy for 
aniridia in light of recent developments, suggesting an approach based principally on chromosomal array and gene panel 
testing. This strategy aims to test all known aniridia loci—including the rarer, life-limiting causes—whilst remaining simple 
and practical.
Structure and development of the human 
iris
Sitting between the cornea and lens of the eye, the adult 
human iris is a 12 mm vivid, multilayered and photoprotec-
tive disc. Through control of pupil size in response to light 
or accommodation, it regulates light passage to the retina 
and is an optical requirement for sharp vision. It lies ante-
rior to the ciliary body and itself plays a structurally impor-
tant role in aqueous dynamics and the iridocorneal angle 
configuration, both of which affect intraocular pressure and 
glaucoma risk.
A macroscopic view of the iris shows a central pupil-
lary region demarcated from the ciliary region by the iris 
collarette (Fig. 1). The sphincter muscle, responsible for 
miosis (constriction) under parasympathetic nervous con-
trol, lies in this inner pupillary region, whereas the dilator 
muscle, which produces sympathetically mediated mydria-
sis, lies in the more peripheral ciliary region.
Of the principal components of the iris, the bilayered epi-
thelium and smooth muscle have a different embryological 
origin to the overlying stroma.
The iris pigmented epithelium is neuroectodermal, devel-
oping as an outgrowth from the margins of the optic cup 
from the third month of gestation—relatively late compared 
to the rest of the eye (Fig. 1). Specification of iris progenitor 
cells to a non-neuronal fate is accompanied by the expres-
sion of transcription factors including PAX6 and OTX1, and 
of members of the Wnt signalling pathway (Liu et al. 2007; 
reviewed by Davis-Silberman and Ashery-Padan 2008). 
Notch genes are also implicated in this patterning (Bao and 
Cepko 1997). Recently, two members of the TGFβ super-
family (Bmp4 and Tgfβ2) and Foxc1 have been identified as 
direct downstream targets of Pax6 in murine iris develop-
ment (Wang et al. 2016). In addition to evidence that they 
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are expressed in mouse iris development (Chang et al. 2001; 
Adams et al. 2007; Hägglund et al. 2017), BMP4 and BMP7 
are highly expressed in developing chick iris smooth muscle 
(Jensen 2005). The iris sphincter and dilator muscles are rare 
examples of ectodermally derived muscle (Imaizumi and 
Kuwabara 1971; Jensen 2005). They are not fully formed 
histologically in human fetuses until the sixth and eight 
months, respectively (Mann 1925).
By contrast, the pupillary membrane and iris stroma 
are mesenchymal in origin, arising from the third wave of 
migrating neural crest cells (Williams and Bohnsack 2015). 
During the second month of gestation, after separation of 
the lens but before the appearance of iris epithelium, a thin 
layer of mesodermally derived tissue is visible anterior to 
the lens (Mann 1925). The central part of this will become 
the pupillary membrane, which regresses late in gestation. 
Mesenchymal cells migrate along the anterior border of 
the iris epithelium, along with stromal melanocytes also 
deriving from neural crest (Sturm and Larsson 2009). Reti-
noic acid and its downstream target PITX2 are critical to 
regulating neural crest derivatives in the anterior segment 
(Williams and Bohnsack 2015). PAX6 is also expressed 
during morphogenesis of this part of the iris, though in a 
more transitory manner and at lower levels than in the ecto-
dermal tissues (Cvekl and Tamm 2004). The Small eye rat 
(rSey) shows impaired migration of neural crest cells from 
the future anterior midbrain to the eye rudiment (Matsuo 
et al. 1993).
Fig. 1  The structure and development of the human iris. a Cartoon 
of the iris musculature, showing the position of the sphincter (shaded 
yellow) and dilator muscles. b Macroscopic photo of normal adult iris 
(courtesy of Chris Moody), showing the inner pupillary portion and 
outer ciliary portion. c Cartoon of the developing eye in a 7–8-week-
old human embryo, showing the migration of periocular mesenchy-
mal cells (shaded in teal) into the developing anterior chamber, which 
will go on to form the mesenchymal iris, pupillary membrane and 
corneal endothelium and stroma. The tips of the optic cup are shaded 
in purple showing the specification of iris epithelial progenitor cells. 
d Cartoon of developing human eye at 4–5 months’ gestation, show-
ing the iris growing out from the optic cup margins. The iris muscu-
lature (shaded orange) is just starting to develop. e Cartoon of adult 
eye, showing a well-formed anterior chamber and iridocorneal angle; 
the iris stroma, musculature (orange) and epithelium (black); lens 
attached by zonules to the ciliary muscle. The cartoons in a, b are 
derived from multiple sources (primarily Mann 1925)
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The striking visible colour of the iris is directly related to 
both the concentration of pigment within iris stromal mel-
anocytes, and the type of melanin (eumelanin:pheomelanin 
ratio) (Prota et  al. 1998). Final adult eye colour is not 
reached at birth, with iris stromal development continuing 
postnatally. In Caucasian infants, the iris is bluer for the 
initial months of life due to lower stromal melanin content 
(Rennie 2012). Genetically, the OCA2-HERC2 region of 
chromosome 15q explains the large majority of variation in 
human eye colour (Sturm and Larsson 2009).
Classical aniridia
Clinical features
First described in 1818 (Barratta 1818), classical aniridia is 
a dominantly inherited, usually bilateral, panocular malfor-
mation (OMIM 106210). Two comprehensive Scandinavian 
studies have shown a prevalence of between 1 in 40,000 and 
72,000 live births (Grønskov et al. 2001; Eden et al. 2008), 
in keeping with older US epidemiological data (Shaw et al. 
1960). The term aniridia can refer to both the clinical sign 
and the condition (Table 1). The latter is a spectrum com-
prising aniridia with foveal plus or minus optic nerve hypo-
plasia, with later development of cataracts, glaucoma and/
Table 1  Definition of terms used in the description of aniridia and related eye malformations
OCT optical coherence tomography
Term Working definition
Iris
 Aniridia 1. (Clinical sign) Absence of the iris
2. (Disease) Panocular eye malformation
 Complete aniridia Absence of the iris, with no visible iris tissue (distinction is not made depending on whether any remnant is detectable 
goniscopically)
 Partial aniridia Incomplete aniridia with some visible iris rim (e.g., in classical aniridia) or, less commonly, absence of part of the iris 
(e.g., in Gillespie syndrome; this is a distinct phenotype to classical aniridia consisting of aplasia of the sphincter)
 Iris hypoplasia Unlike aniridia, this is a neutral term which does not imply any particular associated condition. In the context of 
aniridia, used to describe the minor end of the spectrum of hypoplasia of the iris (cf partial to complete aniridia). 
The mildest sign of this is iris transillumination
 Congenital mydriasis Fixed dilated pupils. In Gillespie syndrome this is due to aplasia of the sphincter
 Iris coloboma Approximately 6 o’clock defect in the iris resulting from failure of optic fissure closure
 Iridolenticular strands Strands of tissue between the iris and the lens, often seen in Gillespie syndrome or anterior segment dysgeneses
 Corectopia Displacement of the pupil, which may be misshapen
Other anterior segment
 Posterior embryotoxon An abnormality of the iridocorneal angle resulting in an anteriorly displaced Schwalbe’s line. Characteristic of Axen-
feld–Rieger syndrome but seen in 15% normal eyes
 Keratopathy A general term for corneal pathology. In the context of aniridia, this is progressive opacification of the cornea over 
many years, related to limbal stem cell failure
Congenital corneal 
opacification
Congenital corneal opacification may result from aniridia and from other developmental anomalies of the anterior seg-
ment such as failure of lens separation. Terms such as Peters anomaly and sclerocornea are clinical signs and are not 
helpful aetiologically. The authors recommend the classification outlined by Nischal (2015)
 Cataract Congenital or acquired lens opacity, with the visual prognosis and need for surgery depending on the age of onset, 
symptoms, morphological type and laterality
Posterior segment
 Foveal hypoplasia Failure of the specialisation of the centre of the macula for fine detailed central vision, visible on OCT as an absent or 
shallow foveal dip. A core feature of aniridia (but not Gillespie syndrome) and ocular albinism
 Optic nerve hypoplasia Visible fundoscopically as a small optic disc, classically with a peripapillary halo and altered ring of pigmentation, 
with reduced vision correlating not with disc size but with papillomacular nerve fibre integrity
 Optic nerve coloboma Excavated optic disc anomaly due to defective optic fissure closure and thus deeper inferiorly, which may involve the 
whole disc and/or coexist with chorioretinal coloboma and microphthalmia
Other
 Ptosis Drooping of the upper eyelid
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or keratopathy. Ptosis is also sometimes seen as a feature, 
as in Fig. 2.
The typical iris phenotype is of complete (Fig. 2) or 
partial aniridia, often with a thin crescent of iris visible. 
Lesser degrees of iris hypoplasia are also seen. The distinc-
tion between partial and total aniridia is of limited use as, 
armed with a gonioscopy lens to view the iridocorneal angle, 
even those with apparently complete aniridia tend to have a 
detectable iris stump (Nelson et al. 1984). However, cases 
of apparent partial aniridia with aplasia of the sphincter and 
a scalloped margin are important to note diagnostically (see 
“Gillespie syndrome” section below).
Whilst congenital glaucoma presenting with buphthalmos 
is rare in aniridia, glaucoma occurs in approximately half of 
aniridia patients, in later childhood or in adulthood (Grant 
and Walton 1974). Mechanisms of glaucoma described in 
aniridia include open angle glaucoma, rotation of the iris 
stump causing synechial chronic angle closure, and goni-
odysgenesis (Netland 2015). Furthermore, some patients 
undergo childhood cataract surgery which itself carries an 
independent risk of secondary glaucoma (Mataftsi 2016). 
The whole spectrum of cataract morphology is seen in 
aniridia, but they are often polar and associated with capsu-
lar fragility that render cataract surgery more difficult (Sch-
neider et al. 2003). Lens subluxation also occurs.
Interestingly, foveal hypoplasia in aniridia occurs with-
out the chiasmal misrouting seen in albinism (Neveu et al. 
2005). Foveal hypoplasia usually results in reduced vision, 
at the level of at least 6/30 (0.7 logMAR), such that most 
patients are eligible for sight impairment registration. The 
optical consequences of lack of iris tissue also contribute to 
this, and strabismic amblyopia (lazy eye) is frequently seen.
Lastly, abnormal corneal epithelial homeostasis and lim-
bal stem cell deficiency in aniridia lead to progressive kera-
topathy (Douvaras et al. 2013). Signs of aniridic keratopa-
thy are typically apparent from early adulthood, the cornea 
becoming slowly more cloudy and vascularised. This con-
stitutes the main cause of progressive visual loss in later life 
(Mayer et al. 2003). Rarely, a congenital corneal opacity may 
be present due to keratolenticular apposition (Nischal 2015).
Whilst other ocular phenotypes such as microphthalmia 
are seen in conjunction with PAX6 mutations (discussed 
below), this is not considered part of the classical aniridia 
phenotype. Non-ocular phenotypes, in particular neuro-
anatomical and endocrine abnormalities (both potentially 
asymptomatic) have been identified in studies of aniridia 
patients. Impaired glucose tolerance has been reported in 
aniridia (Yasuda et al. 2002), and the prevalence of diabe-
tes may be slightly higher [7% vs 4.5%, though note that 
the populations of these studies are not directly comparable 
(Netland et al. 2011; Menke et al. 2015)]. This is supported 
by functional and animal work on the role of Pax6 in the 
pancreas (Swisa et al. 2017). Subtle deficits in olfaction and 
hearing have been described (Sisodiya et al. 2001; Bamiou 
et al. 2007). MRI brain studies have shown structural abnor-
malities on MRI in the pineal gland, anterior commissure, 
Fig. 2  Iris phenotypes in classical aniridia, Gillespie syndrome and 
multisystemic smooth muscle dysfunction syndrome. a Right eye of 
an individual with classical aniridia, showing near complete absence 
of the iris and mild ptosis (image courtesy of David Hall); b iris of a 
Gillespie syndrome patient with an ITPR1 mutation. Note the scal-
loped edge of the iris remnant (arrow), with aplasia of the iris central 
to the collarette (image courtesy of Abhijit Dixit); c iris of a patient 
with an ACTA2 mutation and multisystemic smooth muscle dysfunc-
tion syndrome, showing the aplasia of the iris central to the collarette, 
with a scalloped pupillary margin and iridolenticular strand (arrow) 
(image courtesy of Françoise Meire)
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corpus callosum and frontoparietal cortical areas (Mitchell 
et al. 2003; Free et al. 2003; Yogarajah et al. 2016). These 
are primarily radiological studies with no, or limited (Yoga-
rajah et al. 2016), evidence of potential functional conse-
quences. However, there is evidence of auditory interhemi-
spheric transfer deficits in children with aniridia (Bamiou 
et al. 2007).
Identification of PAX6
Classical aniridia is strongly associated with heterozygous 
loss-of-function of PAX6 (Paired box 6, OMIM 607108, 
hg38 chr11:31784792–31811353). Animal models and 
human patients were key to the identification of this gene in 
the early 1990s (Hanson et al. 1994). The 25th anniversary 
was recently commemorated in a review (Cvekl and Cal-
laerts 2017).
Comparative mapping data had suggested that human 
aniridia was homologous to the murine Sey phenotype (van 
der Meer-de Jong et al. 1990; Glaser et al. 1990), a strain 
first reported in 1967 as having microphthalmia in heterozy-
gotes (Roberts 1967)—and later shown to also feature iris 
hypoplasia, cataracts and corneal opacification (Jordan et al. 
1992). Pax6 was isolated along with other Pax genes from 
mouse expression libraries (Walther et al. 1991). In paral-
lel, the gene was independently identified from positional 
cloning and shown to be deleted in human aniridia (Ton 
et al. 1991). Concurrent analysis of Sey alleles confirmed 
the causal link between Pax6 and semidominant Sey (Hill 
et al. 1991).
Establishing the link between human PAX6 mutations 
and the semidominant Sey, the authors (Hill et al. 1991) 
first observed the importance of dosage sensitivity. More 
recently, this property has been quantified with a haploin-
sufficiency metric by the Exome Aggregation Consortium 
(ExAC) (Lek et al. 2016), with an impressive probability of 
loss-of-function intolerance score, pLI, of 1.00 for PAX6. 
Whilst PAX6 haploinsufficiency leads to aniridia, whole-
gene duplication causes non-aniridic eye malformations, and 
homozygous loss-of-function is perinatally lethal in humans 
and mice (Roberts 1967; Glaser et al. 1994; Schedl et al. 
1996; Aalfs et al. 1997; Schmidt-Sidor et al. 2009; Schilter 
et al. 2013).
PAX6 biology and structure
PAX6 is a highly conserved transcription factor critical to 
the control of both ocular and neural development (Prosser 
and van Heyningen 1998). In addition to orchestrating the 
developing eye, it is expressed in the central nervous system 
and pancreas, as well as in adult tissues such as the cor-
nea, brain and pancreas where it is involved in homeostasis 
(Sivak et al. 2003; Hart et al. 2013; Yogarajah et al. 2016; 
Huettl et al. 2016; Maurya and Mishra 2017).
The canonical human PAX6 encodes a 422 amino acid, 
46.7 kDa protein [UniProt P26367-1 (The UniProt Consor-
tium 2017)], whilst the less abundant, alternatively spliced 
PAX6(5a) isoform (436 amino acid, 48.2 kDa, UniProt 
P26367-2) contains an extra 14 residues between Gln47 
and Val48, encoded by exon 5a (Fig. 3a). PAX6 contains 
two DNA-binding domains, the bipartite paired domain 
(Fig. 3b) and the homeodomain, as well as a proline–ser-
ine–threonine-rich C-terminal transactivation domain. The 
paired and homeodomains can bind to DNA both coopera-
tively and independently, widening the repertoire of targets 
(Jun and Desplan 1996). A third isoform has been identified 
arising from an additional internal promoter (Carrière et al. 
1995; Kim and Lauderdale 2006), though the role of such 
isoforms in humans, potential transcripts of which have been 
identified in silico, remains an interesting question (Bandah 
et al. 2008).
The subcellular localisation of PAX6 is predominantly 
nuclear. Nuclear localisation signals have been identified in 
the paired domain and near the homeodomain (Ploski et al. 
2004; Tabata et al. 2018). However, non-nuclear localisation 
has also been observed. In chick retina, PAX6 was nuclear 
in the ganglion cell and inner nuclear layers, and cytoplas-
mic in the photoreceptor and outer nuclear layer (Shin et al. 
2003), which may reflect its roles in diverse cellular pro-
cesses (Simpson and Price 2002). In quail and nematode, 
paired-less isoforms are found in the cytoplasm (Carrière 
et al. 1995; Zhang et al. 1998). In the mouse brain, SPARC 
and Pax6 have been shown to co-localise and physically 
interact, and the authors suggest a model in which SPARC 
facilitates nuclear-cytoplasmic shuttling of Pax6 (Tripathi 
and Mishra 2010), a role that has also been shown for Karyo-
pherin 13 (Ploski et al. 2004).
In PAX6(5a), the additional 14 amino acids between 
alpha helices 2 and 3 of the paired domain modulate its 
binding and transactivation potential, preferentially binding 
DNA with the C-terminal subdomain, acting as a molecular 
toggle (Epstein et al. 1994; Azuma et al. 1999). The ratio of 
PAX6(5a) to canonical PAX6 is higher in adult than embry-
onic tissue (Kozmik et al. 1997), with the PAX6(5a) isoform 
having a potential role in postnatal eye development (Singh 
et al. 2002). It is possible that other PAX6 transcripts whose 
function is currently uncertain may also have a regulatory 
role.
PAX6 is thus able to increase its target diversity by 
alternative splicing as well as through the use of different 
DNA-binding domains (Simpson and Price 2002). Further-
more, fine-tuning is achieved through cooperative binding 
with other transcription factors, such as SOX2 (Kondoh 
et al. 2004; Hu et al. 2017). Targets of Pax6 include tran-
scription factors [e.g., Six3 (Goudreau et al. 2002) and 
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Foxc1 (Wang et al. 2016)], signalling molecules (e.g., 
Wnt) and crystallins [e.g., alpha A-crystallin (Cvekl et al. 
1994)]; for targets in iris development see above. These 
PAX6 target genes give rise to diverse ocular phenotypes 
when mutated in humans: missense mutations in SIX3 
cause microphthalmia, coloboma and holoprosencephaly 
(MIM #157170); FOXC1 mutations cause anterior seg-
ment dysgenesis (MIM #601631), and alpha A-crystal-
lin (CRYAA) mutations cause cataract (MIM #604219). 
Equally, heterozygous mutations of SOX2, BMP4 and 
MAB21L2 are associated with syndromic microphthalmia 
(MIM #206900, #607932 and #615877, respectively).
Some of the PAX6 gene regulatory networks have been 
elucidated. An elegant and phenotypically relevant exam-
ple is that reciprocal inhibition between Pax6 and Pax2 
establishes the retinal-optic nerve boundary in mammals 
(Schwarz et al. 2000); PAX2 mutation causes papillorenal 
syndrome in humans (MIM #120330). More recently, 
Pax6 was shown by ChIP to directly regulate Prox1 and 
Mab21l1 as part of a lens differentiation network (Sun 
et al. 2015).
Transcriptional activation of PAX6 requires the coordi-
nated activity of cis-regulatory elements, which are mostly 
conserved across mammals and zebrafish (Kleinjan et al. 
2004; Lakowski et al. 2007). These were initially identified 
via human translocation cases, detailed below.
PAX6 mutation spectrum
Reflecting the many possible ways of disrupting PAX6 func-
tion, 472 unique sequence variants are reported (LOVD 
PAX6 database, version 170616, http://lsdb.hgu.mrc.ac.uk/
home.php?selec t_db=PAX6). All classes of sequence varia-
tion are present and no domain of the protein is spared. The 
ten commonest aniridia variants are marked in Fig. 3. The 
wider range of phenotypes spans from mild iris hypoplasia 
to perinatal lethality.
Monoallelic mutations
Likely gene‑disruptive variants The commonest intragenic 
variants are encoded by single nucleotide substitutions 
resulting in a premature termination codon (PTC), with 
p.Arg240*, p.Arg317* and p.Arg203* being the three most 
frequently reported (129 reports in the LOVD database); 
these mutational hospots correspond to CpG dinucleotides 
(Tzoulaki et  al. 2005). Frameshifting insertions, deletions 
and duplications, as well as many splice site mutations, 
Fig. 3  a Protein bar showing the canonical 422-amino acid human 
PAX6 protein, annotated with the ten commonest aniridia alleles. The 
domains and main secondary structural elements are shown (UnitProt 
P26367). The coding exons are 4–13, with exon boundaries indicted 
by a white vertical line. The location of exon 5a, part of the alterna-
tively spliced isoform PAX6(5a), is indicated. b PAX6 paired domain 
bound to dsDNA. Note the two subdomains, each containing three 
alpha helices [PDB ID: 6PAX (Xu et al. 1999), from http://www.rcsb.
org. Image of “6PAX” created using Protein Workshop (Moreland 
et al. 2005)]
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also fall into this category of likely gene-disruptive vari-
ants. PTCs > 50–55 nucleotides upstream of the last coding 
exon–exon junction are predicted to be subject to nonsense-
mediated decay (NMD). Though there could be exceptions 
to this NMD rule (Isken and Maquat 2007; Kervestin and 
Jacobson 2012), the known truncating mutations in humans 
phenocopy null alleles (Tzoulaki et  al. 2005). In addition 
to the classical aniridia phenotype described above, some 
likely gene-disruptive variants appear to be hypomorphic, 
though milder phenotypes appear to be more common with 
missense variants (Hingorani et al. 2009).
Missense variants Missense mutations in PAX6, which may 
lead to production of a full-length protein with altered struc-
ture and function (Mishra et al. 2002), have been published 
associated with both classical aniridia and non-classical phe-
notypes. These include optic nerve anomalies (Nallathambi 
et al. 2006), hypomorphic phenotypes such as ectopia pupil-
lae (Hanson et al. 1999) and, more severely, microphthalmia 
(reviewed in Williamson and FitzPatrick 2014; Chassaing 
et al. 2014). In addition to canonical PAX6, two missense 
variants in the PAX6(5a) isoform have been described in 
five Japanese families (at least three unrelated) with congen-
ital corneal opacification with or without foveal hypoplasia 
and cataract: p.5aGlu13Arg (1 case) (Nanjo et  al. 2004), 
the rest p.5aVal7Asp, with functional work suggesting sub-
tle changes in binding by PAX6(5a) and transactivation 
(Azuma et al. 1999). The structural and functional protein 
consequences of many of the missense variants in the data-
base (in addition to many splice site and in-frame deletions) 
have not been determined experimentally. The functional 
consequences of missense mutations, unlike most PTCs, are 
dependent on their location within the protein. For example, 
missense mutations at the C-terminal amino acid of PAX6 
impair transactivation mediated through the homeodomain 
(Singh et al. 2001).
C‑terminal extensions Frameshift duplications and substi-
tutions predicted to result in C-terminal extensions are nota-
bly common (34 database reports; Fig. 3), some with vari-
ant phenotypes including exudative retinopathy (Hingorani 
et al. 2009).
Larger deletions and  chromosomal rearrangements Chro-
mosomal rearrangements and whole/partial gene deletions 
disrupting PAX6 account for approximately one-third of 
sporadic aniridia cases, and are also found in some famil-
ial cases (Crolla and van Heyningen 2002), such that over-
all these account for approximately 10% all aniridia cases 
(Robinson et al. 2008; Bobilev et al. 2015). Contiguous gene 
deletions causing WAGR syndrome are discussed below.
Variants disrupting the  cis‑regulation of  PAX6 Via analy-
sis of translocation and inversion breakpoints in aniridia 
patients, several disease-causing alleles were identified 
which disrupt the long-range regulation of PAX6. These 
were located 11 kb, 22 kb (Lauderdale et al. 2000), 125 kb 
and 150  kb (SIMO element) (Simola et  al. 1983; Fantes 
et al. 1995) downstream (telomeric) to PAX6. Analysis of 
the SIMO element showed that this is an autoregulatory 
binding site whose disruption impairs PAX6 maintenance 
(Bhatia et al. 2013). The phenotypes were identical to het-
erozygous deletion or PTC-causing mutations of PAX6. 
Mutations in PAX6 regulatory regions are now more easily 
detectable by array-based comparative genomic hybridisa-
tion. Ansari et al. identified five aniridia patients with dele-
tions involving plausible regulatory regions and suggest 
a ‘critical region’ for transcriptional activation spanning 
244 kb (Ansari et al. 2016).
Biallelic mutations
Biallelic mutations in PAX6 with two likely gene-disruptive 
alleles cause severe CNS defects with anophthalmia and 
perinatal lethality (Glaser et al. 1994; Schmidt-Sidor et al. 
2009). A similarly severe ocular phenotype was reported 
in a viable compound heterozygous child with trisomy 21 
(Solomon et al. 2009). Two viable compound heterozygotes 
families have been published with aniridia or coloboma, and 
no severe systemic effects, through having a combination of 
a likely gene-disruptive and presumed mildly hypomorphic 
missense allele (Grønskov et al. 1999; Chao et al. 2003).
Other forms of PAX6‑related eye disease
Distinct phenotypes described in association with PAX6 
mutations include Peters anomaly and other anterior seg-
ment dysgeneses (Prokudin et  al. 2014), coloboma and 
microphthalmia (Williamson and FitzPatrick 2014), optic 
nerve anomalies (Azuma et al. 2003; Nallathambi et al. 
2006), ectopia pupillae and nystagmus (Hanson et  al. 
1999). Commonly seen are the non-iris features of classical 
aniridia, either in isolation or combination, namely cataract, 
foveal hypoplasia, glaucoma and keratopathy (Sale et al. 
2002; Hever et al. 2006). Most of these phenotypes can be 
considered variable expressivity of classical aniridia.
Genetic differential diagnosis of classical aniridia
Whilst classical aniridia is still largely considered a mono-
genic disorder, rarely aniridia-like phenotypes have occurred 
with mutations in two other anterior segment disease genes. 
These include two cases with PITX2 mutations—one intra-
genic (Perveen et al. 2000) and one with a telomeric regula-
tory mutation (Ansari et al. 2016)—and seven cases with 
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FOXC1 mutations. Three of the latter are missense cases (Ito 
et al. 2009; Ansari et al. 2016), and four are whole gene dele-
tions (Sadagopan et al. 2015; Ansari et al. 2016). Of these 
nine aniridia cases, seven had known congenital glaucoma 
(one unknown), many presenting as infants with buphthal-
mos, suggesting that this is more common in FOXC1- than 
PAX6-associated aniridia.
An aniridia family with a segregating missense muta-
tion in TRIM44, ~ 4 Mb away from PAX6 on 11p13, was 
described (Zhang et al. 2015), but we advise caution in 
ascribing pathogenicity as this is a single pedigree supported 
by in vitro functional data. There remains a small but signifi-
cant proportion of aniridia patients with no genetic diagnosis 
(Ansari et al. 2016).
Following an analysis of 42 PAX6-negative aniridia cases 
with array CGH (comparative genomic hybridisation), which 
identified some of the cases above (Ansari et al. 2016), the 
authors were left with 27/42 unexplained cases. Since this 
publication, the Gillespie syndrome cases in this cohort have 
been shown to have ITPR1 mutations (McEntagart et al. 
2016; Gerber et al. 2016). We estimate the proportion of 
unexplained classical aniridia cases to be approximately 5%.
Contiguous deletion syndromes 
encompassing PAX6: WAGR syndrome
Background and clinical features
In 1964, Robert Miller et al. reported the results of a review 
of the case records of 440 individuals with Wilms tumour, 
a rare malignancy of embryonic origin affecting the kidney 
(Miller et al. 1964). Six of these children (1.4%) also had 
aniridia, which was unlikely to be a coincidence given the 
incidence of aniridia at that time of 1 in 50,000 live births 
(Shaw et al. 1960). Each of the children with Wilms tumour 
and aniridia also had significant intellectual disability or 
global developmental delay (termed mental retardation at 
the time). Intellectual disability is not a common associa-
tion in isolated Wilms tumour or classical aniridia. Three 
of the six children had microcephaly and one child had 
contralateral renal hypoplasia. Subsequent to this original 
report, many other cases were published. This constellation 
of clinical features has been named either WAGR syndrome 
(Wilms tumour, aniridia, genitourinary anomalies, mental 
retardation) or AGR syndrome, depending on the presence 
or absence of Wilms tumour. For simplicity, we will use 
WAGR syndrome to cover both groups.
Remarkably few case series or systematic reviews have 
been published which focus on the clinical aspects of 
WAGR. The most useful is a series of 54 clinically well-
characterised individuals (31 males, 23 females) with 
WAGR (Fischbach et al. 2005). Clinical features observed 
in more than two individuals in this series are listed in 
Table 2. Of these non-canonical WAGR features, obesity 
has generated the most clinical interest (Marlin et al. 1994; 
Amor 2002) and has led to the suggestion that WAGR be 
re-designated as WAGRO (Tiberio et al. 2000).
Cytogenetic analysis
Chromosome 11p13 deletions were first identified in three 
individuals with WAGR in 1978 (Riccardi et al. 1978). Fol-
lowing detailed mapping of this chromosome region, the 
causative genes for Wilms tumour and genitourinary anoma-
lies (WT1) (Gessler et al. 1990) and classical aniridia (PAX6) 
(Ton et al. 1991) were found to lie within a megabase of each 
other (Fig. 4). The term “contiguous deletion syndrome” 
is used to describe distinctive patterns of clinical features 
caused by haploinsufficiency for more than one gene map-
ping to the same genomic locus encompassed by a chro-
mosome deletion. WAGR is the paradigm for this type of 
genetic disorder.
WT1 was identified via homozygous intragenic deletions 
in isolated Wilms tumours cases (Gessler et al. 1990). This 
was consistent with WT1 being a tumour suppressor gene 
Table 2  Clinical features associated with WAGR+/−O (excluding 
aniridia, Wilms tumour and intellectual disability): non-canonical 
WAGR features observed in > 2 individuals in a series of 54 WAGR 
cases (Fischbach et al. 2005)
System Feature %
Genitourinary Cryptorchidism 61.3
Respiratory Recurrent sinusitis 27.8
Renal Proteinuria 25.9
Behavioural Short attention span 22.2
Respiratory Obstructive sleep apnoea 20.4
Behavioural Autism spectrum disorders 18.5
Metabolic Obesity 18.5
Dental Severe dental malocclusion 16.7
Ocular Optic nerve hypoplasia 14.8
Musculoskeletal Scoliosis/kyphosis 14.8
Neurologic Hypertonia/hypotonia 13
Genitourinary Hypospadias 12.9
Renal Focal segmental glomerulosclerosis 11.1
Respiratory Recurrent pneumonia 11.1
Ocular Retinal detachment 9.3
Ocular Strabismus 7.4
Genitourinary Ambiguous genitalia 7.4
Neurologic Epilepsy 7.4
Genitourinary Inguinal hernia 5.6
Musculoskeletal Hemihypertrophy 5.6
Metabolic Hyperlipidemia 5.6
Abdominal Chronic pancreatitis 5.6
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operating in a manner consistent with the “two hits hypoth-
esis” (Knudson 1971; Haber et al. 1990), which requires 
inactivation of both copies of the gene in the relevant tissue 
to initiate tumourigenesis. WT1 encodes a zinc finger pro-
tein (Wilms tumour protein, UniProt P19544) which func-
tions as a transcription factor and an RNA-binding protein. 
Heterozygous intragenic, dominant-negative mutations in 
WT1 have been identified in several overlapping develop-
mental disorders characterised by Wilms tumour, genital 
malformations, male-to-female sex reversal, nephropathy, 
diaphragmatic hernia and gonadoblastoma (Pelletier et al. 
1991; Hastie 1992).
The gene—or genes—responsible for the cause of the 
neurodevelopmental problems and obesity in WAGR is not 
yet confirmed. Several lines of evidence implicate the gene 
encoding brain-derived neurotrophic factor (BDNF) in both 
these components of WAGR (Xu et al. 2008; Han et al. 2008, 
2013; Shinawi et al. 2011; Rodríguez-López et al. 2013). 
Heterozygous Bdnf knockout mice have hyperphagia, obe-
sity and poorer learning and social behaviours (Lyons et al. 
1999; Kernie et al. 2000). In humans, WAGR patients with 
BDNF haploinsufficiency had reduced cognitive functioning, 
lower adaptive behaviour and higher levels of obesity, com-
pared to those without a BDNF deletion (Han et al. 2008, 
2013). The BDNF locus was also identified as a GWAS 
hit for obesity (Wen et al. 2012). The genes SLC1A2 and 
PRRG4 have also been implicated in the neurodevelopmen-
tal component (Xu et al. 2008). PAX6 itself has also been 
proposed, given its known involvement in CNS develop-
ment and the small proportion of cases with intragenic PAX6 
mutations associated with developmental delay or autism 
(collated by Davis et al. 2008; Chien et al. 2009).
Relevance to isolated aniridia
Aniridia is usually apparent from soon after birth. Although 
WAGR-associated deletions represent a rare subset of causa-
tive alleles resulting in haploinsufficiency for PAX6, it is 
important to identify such deletions as soon as possible as 
they have a significant impact on both prognosis and man-
agement during infancy and beyond (Fig. 6). Most obvi-
ously, individuals who have deletions encompassing both 
PAX6 and WT1 should be screened for Wilms tumour as ear-
lier detection almost certainly improves outcome (Pritchard-
Jones et al. 2016). Due to the high incidence of end-stage 
renal failure in this group (Fischbach et al. 2005), lifelong 
monitoring of renal function is recommended. It is also rea-
sonable for an individual with a WAGR deletion to be fol-
lowed up by a paediatrician with expertise in the early recog-
nition and management of intellectual disability and autism.
Gillespie syndrome
Clinical features
Apparent partial aniridia, presenting as congenital mydri-
asis, is an invariant feature of Gillespie syndrome (GS; 
OMIM 206700), in association with non-progressive cer-
ebellar hypoplasia and ataxia, intellectual disability and 
congenital hypotonia. In GS the iris defect is bilateral and 
has a distinct scalloped appearance resulting from aplasia 
of the tissue central to the collarette (Fig. 2b). This apla-
sia appears to be a consequence of abnormal development 
of the ectoderm-derived sphincter musculature and the 
Fig. 4  Molecular pathology of WAGR syndrome. Cartoon of the 11p 
genomic region which encompasses PAX6, WT1 and BDNF. The 
numbers and lines at the top represent the hg19 human genomic coor-
dinates, below which are the gene models. If the gene is an OMIM 
morbid gene the cognate OMIM number is given below the gene 
symbol. The boxed genes are those that have been confidently associ-
ated with components of the WAGR syndrome. The bar at the bot-
tom is an empirically-derived critical region for deletions associated 
with WAGR. However, it is likely there are many possible causes of 
the intellectual disability associated with WAGR, so it is reasonable 
to consider that any deletion which encompasses PAX6 and WT1 may 
be WAGR-associated
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surrounding mesoderm-derived stromal tissues at the distal 
tip of the foetal iris. In contrast to PAX6-associated aniridia, 
the ocular defects in GS are essentially restricted to the iris 
and the variable presence of iridolenticular strands. Foveal 
hypoplasia is rarely observed (McEntagart et al. 2016).
Additional phenotypes are noted infrequently, but mul-
tiple cases have shown cardiac (pulmonary valve stenosis, 
patent foramen ovale), skeletal (affecting the vertebrae or 
digits), and gastro-oesophageal defects (Dentici et al. 2017; 
reviewed by Carvalho et al. 2017). The early clinical reports 
of this syndrome were limited to 12 families (reviewed by 
Mariën et al. 2008), and they supported X-linked, autosomal 
recessive and autosomal dominant modes of inheritance.
Identification of ITPR1 as the causal gene
In 2016, two independent projects utilising whole exome 
sequencing concurrently identified ITPR1 (inositol 
1,4,5-trisphosphate receptor type 1; OMIM 147265; hg38 
chr3:4493348–4847840) as the causative gene in GS 
(McEntagart et al. 2016; Gerber et al. 2016). These projects 
studied one familial mother–daughter transmission (Mariën 
et al. 2008) and 15 singleton cases, with a further five cases 
reported subsequently (Zambonin et al. 2017; Dentici et al. 
2017; Carvalho et al. 2017). GS is now considered a mono-
genic disorder, as all 22 reported cases with genetic testing 
had monoallelic or biallelic pathogenic mutations identified 
in ITPR1. Interestingly, 17 of these cases were known to be 
female, although such a marked sex bias was not evident in 
the families described in the early clinical reports with no 
genetic diagnosis. There is no evidence for non-penetrance 
for ITPR1 mutations in GS: all individuals with a pathogenic 
mutation are affected.
ITPR1 biology and structure
The ITPR1 receptor is a type I intracellular transmembrane 
calcium release channel that is inositol 1,4,5-trisphosphate 
(IP3) responsive [UniProt Q14643, alternative names IP3R1, 
InsP3R1; reviewed by Patel et al. (1999)]. The subcellular 
localisation of the receptor is perinuclear: it is primarily in 
the smooth endoplasmic reticulum (ER), though intranu-
clear, possibly nucleoplasm reticular, ITPR1 foci have also 
been reported (Maeda et al. 1990; McEntagart et al. 2016). 
The ITPR1 protein complex is a homotetramer: each subunit 
is oriented with a large N-terminal region, containing an 
IP3-ligand binding site, and a short C-terminal region, both 
in the cytoplasm; six transmembrane domains contributing 
to the channel pore in the ER membrane, and inter-trans-
membrane domain loops in the ER lumen (Jiang et al. 2002). 
The different subtypes of ITPR are ubiquitously expressed, 
with high levels of ITPR1 in the brain and particularly in 
the Purkinje cells of the cerebellum (Maeda et al. 1990). 
The expression pattern in the developing iris is not reported. 
ITPR1 channel function shows calcium-dependent increased 
inhibition when the receptor is bound to the ITPR interact-
ing protein (ITPRIP, previously called DANGER; UniProt 
Q8IWB1), which is highly co-expressed in Purkinje cells 
and contains an ER/plasma membrane signal peptide and a 
conserved partial Mab21 domain (van Rossum et al. 2006). 
In mouse models of Itpr1 null alleles, heterozygosity elicits 
mildly impaired motor coordination and minor iris defects 
distinct from those of GS (Ogura et al. 2001; McEntagart 
et al. 2016), and homozygosity is embryonic lethal or causes 
severe ataxia and seizures with early death (Matsumoto et al. 
1996; reviewed by Tada et al. 2016).
ITPR1 mutation spectrum
In GS, ITPR1 mutations have been identified in four fami-
lies with recessive homozygous or compound heterozygous 
alleles, and in 16 families with dominant heterozygous 
alleles (McEntagart et al. 2016; Gerber et al. 2016; Zam-
bonin et al. 2017; Dentici et al. 2017; Carvalho et al. 2017). 
The families with dominant mutations include the one famil-
ial case, with mother–daughter transmission, and a de novo 
event in a consanguineous family. Parental DNA was avail-
able for all but one of the remaining dominant families, and 
de novo occurrence of the mutation was established in each 
case. The recessive alleles are predicted to generate pre-
mature termination codons that, possibly via exon skipping 
mechanisms, appear to act as partial rather than full loss-
of-function mutations; as the carrier parents of these alleles 
are unaffected there is no apparent haploinsufficient effect 
associated with these hypomorphic variants (see below for 
ITPR1 haploinsufficiency in non-GS ataxia; Fig. 5).
Given that less than 50% of normal levels of ITPR1 are 
necessary to cause GS, it was proposed that the dominant 
heterozygous alleles associated with this syndrome are not 
loss-of-function mutations but are dominant-negative muta-
tions. These dominant alleles comprise missense mutations 
or codon-Lys2596 deletion, and alter C-terminal residues 
that are located at or near the ER transmembrane domain 
and the associated ion-transport region of the channel. The 
restricted and recurrent nature of the dominant Lys2596 
deletion and missense mutations, which substitute residues 
Glu2094, Gly2539, Asn2576, or Phe2586 in the pore of the 
channel (Fig. 5), indicates that these residues are critical for 
ITPR1 function (all numbering from RefSeq Q14643-2, iso-
form 2; 2743 amino acids). In contrast to other pathogenic 
variants, these dominant-negative variants are thought to be 
less destabilising and thereby permit ITPR1 protein complex 
formation but with abrogated function (McEntagart et al. 
2016; Natan et al. 2016). Furthermore, as a consequence of 
the homotetrameric structure of ITPR1, these mutations are 
predicted to generate variant subunits that will incorporate 
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in to 15/16 protein complexes formed. Decreased calcium 
release activity was detected in ITPR1(Lys2596deletion)-
mutant transfected cells; however, the in vivo mechanism(s) 
underlying the altered function of the mutant protein com-
plex in recessive and dominant GS is not known (Gerber 
et al. 2016).
Other forms of ITPR1‑associated disease
Pathogenic mutations in ITPR1 were first described in two 
types of spinocerebellar ataxia (SCA), in which iris devel-
opment is normal. Both of these SCA types are essentially 
dominant conditions. The late onset, slowly progressive 
form, SCA15 (OMIM 606658), results from ITPR1 hap-
loinsufficiency caused mainly by whole gene deletion, but 
also from stop-gain or rare missense mutations (reviewed 
by Tada et al. 2016). The congenital/infantile non-pro-
gressive form, SCA29 (OMIM 117360), is caused by het-
erozygous in-frame, mostly missense, mutations that alter 
residues predominantly in the cytoplasmic N-terminal 
portion of ITPR1 (reviewed by Zambonin et al. 2017). A 
recessive variant, Leu1820Pro, was recently identified in a 
SCA29 consanguineous family, where the carrier individu-
als had asymptomatic cerebellar hypoplasia (Klar et al. 
2017). Furthermore, “GS-like” heterozygous variants that 
substitute residues in the ion-transport channel have been 
identified in cases with SCA (including reported SCA29 
cases with the recurrent GS variant Gly2539Arg) (Valen-
cia et al. 2015; Zambonin et al. 2017; Hsiao et al. 2017), 
pontocerebellar hypoplasia (Hayashi et al. 2017; van Dijk 
et al. 2017) or peripheral neuropathy (Gonzaga-Jauregui 
et al. 2015). De novo substitution variants have also been 
identified in ataxic cerebral palsy cases with normal neuro-
imaging (Parolin Schnekenberg et al. 2015) (Fig. 5). These 
reports demonstrate that recessive and dominant alleles 
of ITPR1 are now associated with both GS and SCA, and 
that additional specific alleles can cause other neurologi-
cal conditions. The genotype:phenotype pattern is diverse 
Fig. 5  Spectrum of ITPR1 pathogenic variants. A linear protein sche-
matic of ITPR1 is shown in the bottom panel, with domains and fea-
tures demarcated and labelled in colour. The position of the 15-amino 
acid insertion in the longer isoform, UniProt Q14643-1, is shown in 
yellow. Amino acid numbering and domain positions are based on 
the 2743-amino acid isoform 2: Q14643-2, encoded by the canonical 
transcript GenBank NM_001168272.1; ENST00000302640. Shown 
above the protein schematic are all of the published variants associ-
ated with Gillespie syndrome and other neurological conditions, and 
all of the published substitution variants associated with spinocer-
ebellar ataxia (SCA). All variants shown have had their amino acid 
numbering unified to isoform 2 (to facilitate an accurate collation 
and comparison of the ITPR1 dataset) and may therefore differ from 
the numbering used in the original publication. Variants in brackets 
indicate recessive alleles, of which *compound heterozygous alleles 
identified in a single proband; **cases reported as having a SCA29 
phenotype and with substitutions at residues associated with Gillespie 
syndrome (identical variant) or pontocerebellar hypoplasia (different 
variant); ***variant associated with adult onset SCA in a mother and 
early onset SCA in her daughter
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Fig. 6  a Flowchart showing an example approach to the genetic 
investigation of new congenital aniridia/congenital mydriasis cases. 
This will usually consist of an aniridia NGS gene panel—in the UK 
this includes PAX6, FOXC1, PITX2 and ITPR1—and copy num-
ber analysis (e.g., chromosomal array or array-based comparative 
genomic hybridisation). The latter is important to look for contigu-
ous deletion of PAX6 and WT1. We have suggested the combina-
tion of iris and cardiac features which should prompt consideration 
of ACTA2 sequencing—this could be tested with other genes such as 
ITPR1 depending on clinical judgement. *Gillespie syndrome-like 
iris (see Fig. 2b, c); **a suggested surveillance regimen for the seri-
ous complications of ACTA2 multisystemic smooth muscle dysfunc-
tion has recently been outlined (Regalado et  al. 2018). b Brief out-
line of the management of aniridia and WAGR syndrome. c Pie chart 
showing the genetic causes of isolated and syndromic aniridia. Note 
that these frequencies are calculated as a percentage of all aniridia 
cases (using the term broadly and including Gillespie syndrome). For 
example, whilst ITPR1 accounts for 2–3% aniridia cases, it is the only 
known cause of Gillespie syndrome. They are estimated and approxi-
mate frequencies derived from published sources (Grønskov et  al. 
2001; Crolla and van Heyningen 2002; Robinson et al. 2008; Bobilev 
et al. 2015; Ansari et al. 2016) or, where no published data is avail-
able, estimated from our cohort of > 400 aniridia patients
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and indicates that the ITPR1 protein complex has multiple 
functional regions that are intricately tissue-specific and 
that can be aberrantly altered by numerous mechanisms.
Differential diagnosis of Gillespie syndrome
Prior to the identification of ITPR1 mutations causing GS, 
two aniridia cases with GS features were reported with PAX6 
mutations: one had a non-coding exon essential-splice muta-
tion and no ataxia or cerebellar abnormalities (Ticho et al. 
2006), and the second, with a typical PAX6 stop-gain muta-
tion, had ataxia but no cerebellar abnormalities (Graziano 
et al. 2007). In both cases, the iris remnant did not have the 
scalloped appearance that is characteristic of GS.
A GS-like iris defect is evident in the fixed dilated pupils 
of individuals with a severe multisystemic smooth muscle 
dysfunction syndrome (OMIM 613834) caused by Arg179 
substitutions in the ACTA2 gene (actin, alpha 2, smooth 
muscle, aorta; OMIM 102620; Fig. 2c) (Roulez et al. 2014; 
reviewed by; Regalado et al. 2018). Cyclic GMP kinase 
signalling complex studies in tracheal smooth muscle have 
indicated an interaction between ITPR1 and alpha-actin 
(Koller et al. 2003); however, functional analyses of these 
two proteins in iris tissue are not reported.
Investigations and clinical management
The investigation and management of aniridia cases are mul-
tidisciplinary, usually involving genetics, paediatric and oph-
thalmology services, and even more so in syndromic cases. 
An example approach to working up new aniridia/congenital 
mydriasis cases is shown in Fig. 6, with general management 
recommendations. For the vast majority of aniridia cases, 
this comprises two tests: an NGS gene panel (that ideally 
includes PAX6, FOXC1, PITX2 and ITPR1) and an assess-
ment of copy number such as array CGH. The array is impor-
tant to detect deletions encompassing WT1, which determine 
the need for continuing Wilms tumour screening (Grønskov 
et al. 2001) and monitoring of renal function. In familial 
aniridia cases, the chance of a WT1 deletion is very low, with 
only two WAGR syndrome familial cases reported (Fantes 
et al. 1992; Robinson et al. 2008). However, the array retains 
excellent diagnostic value, as the high-resolution assessment 
of copy number can detect whole gene or regulatory region 
deletions in PAX6 (or rarely, FOXC1/PITX2) (Ansari et al. 
2016; Blanco-Kelly et al. 2017; Franzoni et al. 2017). We 
therefore have not distinguished between the investigation 
of sporadic and familial aniridia cases, though clearly in 
familial cases where the genetic cause is already known, this 
should be tested directly.
There are two causes of aniridia associated with life-
limiting complications. In WAGR syndrome, Wilms 
tumour survival rates approach 95% at 4 years, but WAGR 
carries a late mortality risk from end-stage renal failure 
(Breslow et al. 2003; Brok et al. 2017). The International 
WAGR Syndrome Association produce a comprehensive 
management summary for physicians including screening 
protocols (http://wagr.org). Individuals with ACTA2 multi-
systemic smooth muscle dysfunction are at risk of acute, 
life-threatening vascular events including aortic dissections 
and ischaemic strokes in childhood (Roulez et al. 2014); it 
is important to identify these rare cases early to instigate 
appropriate surveillance (Regalado et al. 2018).
For patients with a Gillespie syndrome-like iris (Fig. 2b, 
c), the two known genetic causes are ITPR1 and ACTA2 
p.Arg179 substitutions. In most cases, the iris defect is 
detected before the other features of these conditions. How-
ever, there is one clinical feature which can aid the decision 
of whether to test ACTA2 in addition to ITPR1. In the larg-
est series of ACTA2 p.Arg179 cases (33 individuals), the 
only feature reliably present at birth in all cases, other than 
the iris defect, was cardiac: a large patent ductus arteriosus 
(PDA, 91%) or aortopulmonary septal defect (9%). Based on 
this and given the serious prognostic implications, it seems 
reasonable to only test ACTA2 if both the iris and cardiac 
features are present.
One of the principal benefits of NGS gene panels for 
patients with unexplained ocular disease is the number of 
eye genes that can be tested simultaneously and cost effec-
tively. For example, known PAX6 target genes, such as 
BMP4, FOXC1 and SIX3 discussed above—which are not 
aniridia genes but cause diverse eye malformations—can be 
included in such a panel.
If all of the suggested investigations are negative, options 
for pursuing further investigation include looking for bal-
anced chromosome translocations and whole exome or 
whole genome sequencing; depending on availability, the 
latter may be more often pursued in a research rather than 
diagnostic laboratory setting. In addition to the management 
outlined in Fig. 6, optical coherence tomography (OCT) is 
valuable for evaluating foveal hypoplasia, though this is 
postponed until the child can cooperate. Furthermore, MRI 
brain may be helpful in classical aniridia if there are relevant 
neurological symptoms (e.g., olfactory, auditory), as well 
as in Gillespie syndrome. Lastly, it is also helpful to alert 
families to the existence of patient organisations, such as 
Aniridia Network (http://aniri dia.org.uk), Aniridia Europe 
(http://www.aniri dia.eu), Aniridia Foundation International 
(http://www.aniri dia.net) and IWSA (http://wagr.org).
Knowledge of the specific mutation in aniridia may 
become important for determining eligibility for future ther-
apies. Ataluren, which targets in-frame nonsense mutations 
and showed promise in a Sey mouse model with a nonsense 
mutation in the linker region (Gregory-Evans et al. 2014), 
is in phase 2 clinical trials (STAR trial, ClinicalTrials.gov 
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ID NCT02647359) (Wang and Gregory-Evans 2015). Ata-
luren failed to meet the primary endpoint in phase 3 trials for 
cystic fibrosis (Kerem et al. 2014) and Duchenne muscular 
dystrophy (McDonald et al. 2017), but showed benefit in 
a subgroup of the latter. New treatments for the complica-
tions of aniridia are also undergoing evaluation. Surgical 
treatments at the clinical trial stage for aniridia include oral 
mucosal epithelial transplantation (EU Clinical Trials Reg-
ister ID 2011-000598-30) and ex vivo expanded corneal lim-
bal stem cell transplantation (UK Clinical Trial Gateway 
ID, ISRCTN54055321). Both of these aim to treat aniridic 
keratopathy, the principal cause of progressive visual loss, 
and as such have the potential to improve quality of life of 
individuals with aniridia.
Conclusion
In summary, whilst the story of classical aniridia genetics 
took form nearly three decades ago with the identification 
of PAX6, the cause for Gillespie syndrome has only recently 
emerged as ITPR1. The role of the latter in iris develop-
ment is not yet clear, and equally many PAX6-dependent 
gene regulatory networks remain poorly understood. Just as 
PAX6 has served as a model for dosage-sensitive transcrip-
tion factors, WAGR syndrome is a paradigm for contiguous 
deletion syndromes. We have outlined a genetic investigation 
strategy for aniridia and Gillespie syndrome, including copy 
number analysis and gene panel testing, and suggest crite-
ria for testing ACTA2. Lastly, an estimated 5% of classical 
aniridia remains unexplained. These cases may be caused 
by novel mechanisms that disrupt the known genes or by 
mutations at new loci, which may be elucidated by whole 
genome sequencing studies.
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